As a surprisingly high number of newcomers reach successful fund closes despite continued turbulence in the fundraising market, Warren Hibbert of Asante Capital explains how maiden vehicles are finding success where many well-established players are falling by the wayside.
Backers close a $18.6m round started in 2015 with an initial $10.6m capital injection
GP invests via its Nordic Capital Fund IX, which held a final close on €4.3bn in May 2018
Abalos Therapeutics is a biotechnology company focused on developing immuno-oncology therapeutics
Existing management team will lead the company's future growth and development